Tru-cut biopsy for suspected ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial checks if an ultrasound-guided tru-cut biopsy (a small needle sample) is safe and accurate in people with suspected advanced ovarian cancer. It may help avoid more invasive surgery to get a diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have suspected advanced ovarian cancer.
- A team of cancer specialists must decide a tru-cut biopsy is needed.
- You cannot be in the trial if you do not want to have a tru-cut biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing new blood tests that might help detect ovarian cancer earlier by looking for specific markers. It involves people with suspected ovarian cancer and healthy volunteers, and aims to improve how we diagnose the disease.
This study tests whether a transvaginal ultrasound can be used as a screening tool for ovarian cancer in women at higher risk. It may help find ovarian cancer earlier in people who have a strong family or personal cancer history.
This trial studies whether a simple blood test (liquid biopsy) can help tell if an ovarian mass is cancer or not, and if it can catch cancer early. If you're going to have surgery for a suspicious ovarian mass, this test might give extra information to guide your care.
This study is testing a blood test to see if it can catch ovarian cancer early. You may be eligible if you have been recently diagnosed with ovarian cancer and haven't started treatment yet.
This trial tests whether doing surgery with small incisions (minimally invasive) instead of a large cut is safe and effective for advanced ovarian cancer after chemo. It may mean a faster recovery while still removing the cancer.
This study looks at tumor tissue from ovarian cancer patients to find “biomarkers,” or lab signals, that may predict how the disease behaves or how it might respond to treatment. You may be asked for a biopsy of the relapsed (coming back) tumor or to use an existing archived tumor sample.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.